Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan
· Delayed Price · Currency is TWD 100.00
-1.50 (-1.48%)
Apr 2, 2025, 1:30 PM CST
Gongwin Biopharm Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 32.04 | 18.92 | 1.14 | 1.14 | 0.83 | Upgrade
|
Revenue Growth (YoY) | 69.39% | 1554.86% | - | 37.21% | 235.89% | Upgrade
|
Cost of Revenue | 23.36 | 7.72 | 0.08 | 0.07 | 0.05 | Upgrade
|
Gross Profit | 8.68 | 11.2 | 1.07 | 1.08 | 0.79 | Upgrade
|
Selling, General & Admin | 101.56 | 91.88 | 67.43 | 38.85 | 41.89 | Upgrade
|
Research & Development | 63.27 | 52.65 | 194.32 | 83.05 | 76.26 | Upgrade
|
Operating Expenses | 170.74 | 144.53 | 261.75 | 121.9 | 118.15 | Upgrade
|
Operating Income | -162.06 | -133.33 | -260.68 | -120.83 | -117.37 | Upgrade
|
Interest Expense | -4.3 | -7.19 | -3.19 | -1.18 | -0.5 | Upgrade
|
Interest & Investment Income | 64.62 | 41.61 | 6.82 | 2.4 | 4.6 | Upgrade
|
Currency Exchange Gain (Loss) | - | -4.85 | -39.6 | 0.9 | 5.87 | Upgrade
|
Other Non Operating Income (Expenses) | 9.88 | 2.58 | 4.51 | 2.05 | 1.53 | Upgrade
|
EBT Excluding Unusual Items | -91.86 | -101.18 | -292.13 | -116.66 | -105.87 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | 0.74 | 4.68 | Upgrade
|
Other Unusual Items | - | - | - | 1.2 | 1.87 | Upgrade
|
Pretax Income | -91.86 | -101.18 | -292.13 | -114.72 | -99.32 | Upgrade
|
Income Tax Expense | 0.13 | - | - | 15.2 | - | Upgrade
|
Earnings From Continuing Operations | -91.99 | -101.18 | -292.13 | -129.92 | -99.32 | Upgrade
|
Minority Interest in Earnings | 9.44 | - | - | 8.34 | 6.25 | Upgrade
|
Net Income | -82.55 | -101.18 | -292.13 | -121.58 | -93.07 | Upgrade
|
Net Income to Common | -82.55 | -101.18 | -292.13 | -121.58 | -93.07 | Upgrade
|
Shares Outstanding (Basic) | 121 | 113 | 111 | 110 | 104 | Upgrade
|
Shares Outstanding (Diluted) | 121 | 113 | 111 | 110 | 104 | Upgrade
|
Shares Change (YoY) | 7.17% | 1.92% | 1.44% | 4.87% | 1.37% | Upgrade
|
EPS (Basic) | -0.68 | -0.89 | -2.63 | -1.11 | -0.89 | Upgrade
|
EPS (Diluted) | -0.68 | -0.89 | -2.63 | -1.11 | -0.89 | Upgrade
|
Free Cash Flow | -293.3 | -111.7 | -239.54 | -218.52 | -117.4 | Upgrade
|
Free Cash Flow Per Share | -2.42 | -0.99 | -2.15 | -2.00 | -1.12 | Upgrade
|
Gross Margin | 27.09% | 59.21% | 93.26% | 94.31% | 94.36% | Upgrade
|
Operating Margin | -505.80% | -704.87% | -22806.74% | -10570.95% | -14089.56% | Upgrade
|
Profit Margin | -257.64% | -534.89% | -25558.44% | -10637.01% | -11173.11% | Upgrade
|
Free Cash Flow Margin | -915.41% | -590.55% | -20956.69% | -19118.11% | -14093.16% | Upgrade
|
EBITDA | -150.47 | -125.03 | -252.2 | -112.82 | -110.64 | Upgrade
|
D&A For EBITDA | 11.59 | 8.29 | 8.48 | 8 | 6.72 | Upgrade
|
EBIT | -162.06 | -133.33 | -260.68 | -120.83 | -117.37 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.